Charles Theuer - Net Worth and Insider Trading

Charles Theuer Net Worth

The estimated net worth of Charles Theuer is at least $25,763 dollars as of 2024-06-19. Charles Theuer is the President and CEO of TRACON Pharmaceuticals Inc and owns about 19,971 shares of TRACON Pharmaceuticals Inc (TCON) stock worth over $25,763. Details can be seen in Charles Theuer's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Charles Theuer has not made any transactions after 2023-04-27 and currently still holds the listed stock(s).

Transaction Summary of Charles Theuer

To

Charles Theuer Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Charles Theuer owns 3 companies in total, including TRACON Pharmaceuticals Inc (TCON) , Oncternal Therapeutics Inc (ONCT) , and 4D Molecular Therapeutics Inc (FDMT) .

Click here to see the complete history of Charles Theuer’s form 4 insider trades.

Insider Ownership Summary of Charles Theuer

Ticker Comapny Transaction Date Type of Owner
TCON TRACON Pharmaceuticals Inc 2023-04-27 director & President and CEO
ONCT Oncternal Therapeutics Inc 2019-06-07 director
FDMT 4D Molecular Therapeutics Inc 2020-12-10 director

Charles Theuer Latest Holdings Summary

Charles Theuer currently owns a total of 1 stock. Charles Theuer owns 19,971 shares of TRACON Pharmaceuticals Inc (TCON) as of April 27, 2023, with a value of $25,763.

Latest Holdings of Charles Theuer

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TCON TRACON Pharmaceuticals Inc 2023-04-27 19,971 1.29 25,763

Holding Weightings of Charles Theuer


Charles Theuer Form 4 Trading Tracker

According to the SEC Form 4 filings, Charles Theuer has made a total of 37 transactions in TRACON Pharmaceuticals Inc (TCON) over the past 5 years, including 37 buys and 0 sells. The most-recent trade in TRACON Pharmaceuticals Inc is the acquisition of 2,550 shares on April 27, 2023, which cost Charles Theuer around $37,739.

Insider Trading History of Charles Theuer

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Charles Theuer Trading Performance

GuruFocus tracks the stock performance after each of Charles Theuer's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Charles Theuer is 54%. GuruFocus also compares Charles Theuer's trading performance to market benchmark return within the same time period. The performance of stocks bought by Charles Theuer within 3 months outperforms 17 times out of 38 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Charles Theuer's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Charles Theuer

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
10 out of 38 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 30.94 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 29.68 LIMIT LIMIT LIMIT LIMIT LIMIT

Charles Theuer Ownership Network

Ownership Network List of Charles Theuer

No Data

Ownership Network Relation of Charles Theuer

Insider Network Chart

Charles Theuer Owned Company Details

What does TRACON Pharmaceuticals Inc do?

Who are the key executives at TRACON Pharmaceuticals Inc?

Charles Theuer is the director & President and CEO of TRACON Pharmaceuticals Inc. Other key executives at TRACON Pharmaceuticals Inc include 10 percent owner Opaleye Management Inc. , Chief Operating Officer Bonne J. Adams , and Chief Accounting Officer (PAO) Scott B. Brown .

TRACON Pharmaceuticals Inc (TCON) Insider Trades Summary

Over the past 18 months, Charles Theuer made 3 insider transaction in TRACON Pharmaceuticals Inc (TCON) with a net purchase of 62,799. Other recent insider transactions involving TRACON Pharmaceuticals Inc (TCON) include a net sale of 4,589,500 shares made by Opaleye Management Inc. , a net purchase of 3,500 shares made by Scott B. Brown , and a net sale of 120 shares made by William R Larue .

In summary, during the past 3 months, insiders sold 0 shares of TRACON Pharmaceuticals Inc (TCON) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 238,206 shares of TRACON Pharmaceuticals Inc (TCON) were sold and 12,040 shares were bought by its insiders, resulting in a net sale of 226,166 shares.

TRACON Pharmaceuticals Inc (TCON)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

TRACON Pharmaceuticals Inc Insider Transactions

No Available Data

Charles Theuer Mailing Address

Above is the net worth, insider trading, and ownership report for Charles Theuer. You might contact Charles Theuer via mailing address: C/o Tracon Pharmaceuticals, Inc., 4350 La Jolla Village Drive, Suite 800, San Diego Ca 92122.

Discussions on Charles Theuer

No discussions yet.